Stable Q1 for DSM; outlook tough

DSM said that activity for its Pharmaceutical Products business remained low and Q1 sales were stable compared to last year. The company saw lower API sales following the loss of some products, but this was offset by the completion of the H1N1 vaccine shipments. Looking forward, DSM said it expected the full year results to be lower than in 2009 due to ongoing challenges at in the business unit said there were "some very tough quarters ahead".
DSM